Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (202)	4/10/2003 1:32:25 PM
From: dalroi	Read Replies (1) \| Respond to of 447

concerning egfr antagonists in the ESGO yesterday one speaker said the following 1/ all those new biologicals are still way to early 2/ we should find someting like her 2 neu (determine if herceptin will work or not) intrestingly is this breastcancers with her 2 neu positive status have a bad prognosis , what herceptine seems to do is bring prognosis to the same levvel as in her 2 neu negative tumors so we need a marker to see in which patients its gonna work 3/ at the end he said , i 'think one of them is gonna work what we see in colonca gives us a positive clue ... cheers Stefaan